Pharmaceutical composition having synergistic action of direct catalase inhibitors and modulators of no metabolism or of extracellular superoxide anion production which lead to catalase destruction

A pharmaceutical composition for the treatment of a tumor disease via the induction of selective apoptosis in tumor cells associated with said tumor disease in a subject in need thereof, said composition comprising (a) an amount of a first active ingredient that is effective to bring about a singlet oxygen-independent direct catalase inactivation, wherein said first active ingredient is selected from the group consisting of:

• (i) human or humanized antibodies capable of binding to membranous human catalase and (ii) human or humanized antibodies capable of binding to human superoxide dismutase, and (b) an amount of a second active ingredient that is effective to inactivate catalase through modulation of the nitrogen oxide or superoxide anion metabolism of the cells and subsequent singlet oxygen formation, wherein said second active ingredient is selected from the group consisting of:
• taxol, an anthocyanin, and diallyldisulfide, and combinations thereof.